#bispecific — top 20, last 30d
| 0 | 💬 0 |
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
(nejm.org)
|
New England Journal of Medicine 2026-06-13 | #immunotherapy #myeloma #bispecific #clinical trial #antibody | |
| 0 | 💬 0 |
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
(nature.com)
|
Nature Medicine 2026-06-25 | #myeloma #immunotherapy #bispecific #clinical trial #transplantation |